Oral bisphosphonates: early endosseous dental implant success and crestal bone changes. A retrospective study.
OBJECTIVE
The purpose of this retrospective chart-review study was to compare the early success rate and the crestal bone changes of dental implants in patients taking oral bisphosphonates at the time of implant placement to those of patients who had never taken bisphosphonates.


METHODS
A retrospective chart review of 100 women (153 implants) taking oral bisphosphonates at the time of implant placement (test group) and 100 women (132 implants) who had never taken bisphosphonates (control group) was performed to examine overall implant success at the time of stage-two surgery. Radiographic images, which were available for 73 patients in each group and were taken at the time of implant placement and at stage-two surgery, were analyzed to assess and compare crestal bone changes around the implants.


RESULTS
There was no significant difference between groups in the success rates of dental implants at stage-two surgery (test 93.5%, control 95.5%). The change in crestal bone height was statistically significant from the time of placement to stage-two surgery within both groups but was not significantly different between groups (means ± standard deviations: test, 0.66 ± 0.70 mm; control: 0.80 ± 0.65 mm).


CONCLUSIONS
In this study, the use of oral bisphosphonates at the time of implant placement and during healing did not affect early implant success rates or crestal bone changes up to the time of stage-two surgery. In addition, the implant location and the duration of drug therapy at the time of placement were not significant factors in the success rate or bony changes. These conclusions must be viewed in the context of the limitations of the retrospective study design and should be confirmed in longer, more rigorously designed studies.
Department of Periodontics, The University of Texas School of Dentistry at Houston, USA.
Sayma
S
Memon
Robin L
RL
Weltman
James A
JA
Katancik
D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D019386:Alendronate / Q000008:administration & dosage; D016301:Alveolar Bone Loss / Q000000981:diagnostic imaging; D000539:Alveolar Process / Q000000981:diagnostic imaging / Q000187:drug effects*; D000704:Analysis of Variance; D050071:Bone Density Conservation Agents / Q000008:administration & dosage*; D016022:Case-Control Studies; D003758:Dental Implantation, Endosseous / Q000379:methods*; D015921:Dental Implants; D004164:Diphosphonates / Q000008:administration & dosage*; D012968:Etidronic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D000077557:Ibandronic Acid; D008875:Middle Aged; D011859:Radiography; D012189:Retrospective Studies; D000068296:Risedronic Acid
D050071:Bone Density Conservation Agents; D015921:Dental Implants; D004164:Diphosphonates; D000068296:Risedronic Acid; D012968:Etidronic Acid; D000077557:Ibandronic Acid; D019386:Alendronate